Sézary Syndrome Is a Unique Cutaneous T-Cell Lymphoma As
Leukemia (2008) 22, 393–399 & 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00 www.nature.com/leu ORIGINAL ARTICLE Se´zary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3 N Booken1,11, A Gratchev1,11, J Utikal1, C Wei2,XYu3, M Qadoumi1, M Schmuth4, N Sepp4, D Nashan5, K Rass6,TTu¨ting7, C Assaf8, E Dippel1,9, R Stadler10, C-D Klemke1 and S Goerdt1 1Department of Dermatology, Venereology and Allergology, University Medical Centre Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany; 2Institute of Medical Statistics, University Medical Centre Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany; 3Medical Research Center (ZMF), University Medical Centre Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany; 4Department of Dermatology, Innsbruck Medical University, Innsbruck, Austria; 5Department of Dermatology, University of Freiburg, Freiburg, Germany; 6Department of Dermatology, The Saarland University Hospital, Homburg/Saar, Germany; 7Department of Dermatology, University of Bonn, Bonn, Germany; 8Department of Dermatology, Charite-University Medicine Berlin, Berlin, Germany; 9Department of Dermatology, Academic Medical Centre, Lemgo, Germany and 10Department of Dermatology, Academic Medical Centre, Minden, Germany Sezary syndrome (SS) is a rare, aggressive CD4 þ cutaneous While MF usually is a slowly progressive disease, SS runs a more T-cell lymphoma (CTCL); molecular traits differentiating SS aggressive course with a high mortality rate and a median survival from nonleukemic mycosis fungoides (MF) and from inflamma- time of 2–4 years. The probability of survival in CTCL can be tory skin diseases (ID) are not sufficiently characterized.
[Show full text]